Related Experiment Video
Updated: Jul 19, 2025
Depletion and Reconstitution of Macrophages in Mice
Published on: August 1, 2012
SOCS1 Peptidomimetic Alleviates Glomerular Inflammation in MsPGN by Inhibiting Macrophage M1 Polarization
Yinghua Zhao1,2, Fei Peng1,3, Jiayi He1
1Department of Nephrology, First Medical Center of Chinese, State Key Laboratory of Kidney Diseases, PLA General Hospital, Nephrology Institute of the Chinese People's Liberation Army, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Disease Research, Beijing, 100853, China.
Abstract:
Mesangial proliferative glomerulonephritis (MsPGN), the most common pathological change in primary glomerulonephritis, is characterized by increased macrophage infiltration into glomeruli, which results in proinflammatory cytokine release. Macrophage infiltration and differentiation are induced by the Janus kinase 2 and signal transducer and activator of the transcription 1 (JAK2/STAT1) pathway. As a suppressor of cytokine signaling 1 (SOCS1) downregulates the immune response by inhibiting the JAK2/STAT1 pathway, we investigated whether a peptide mimicking the SOCS1 kinase inhibitor region, namely, SOCS1 peptidomimetic, protects against nephropathy. Glomerular JAK2/STAT1 pathway activation was synchronized with kidney injury in an MsPGN rat model. Rats treated with the SOCS1 peptidomimetic exhibited reduced pathological glomerular changes and lessened macrophage recruitment. Moreover, in vivo, the phosphorylation of the JAK2/STAT1 pathway was downregulated in infiltrated macrophages of glomeruli. In vitro, the SOCS1 peptidomimetic inhibited macrophage M1 polarization by suppressing JAK2/STAT1 activation. In conclusion, our study demonstrated that the SOCS1 peptidomimetic plays a protective role against pathologic glomerular changes in MsPGN by reducing macrophage infiltration and inhibiting macrophage polarizing to the M1 phenotype. SOCS1 peptidomimetic, therefore, presents a feasible therapeutic strategy to alleviate renal inflammation in MsPGN.
Insights
A novel SOCS1 peptidomimetic peptide effectively reduced kidney inflammation in a rat model of mesangial proliferative glomerulonephritis (MsPGN). This therapeutic strategy alleviates renal inflammation by decreasing macrophage infiltration and M1 polarization.
Area of Science:
- Nephrology
- Immunology
- Molecular Biology
Background:
- Mesangial proliferative glomerulonephritis (MsPGN) is a common kidney disease characterized by macrophage infiltration and inflammation.
- The Janus kinase 2 and signal transducer and activator of the transcription 1 (JAK2/STAT1) pathway drives macrophage infiltration and differentiation in MsPGN.
- Suppressor of cytokine signaling 1 (SOCS1) inhibits the JAK2/STAT1 pathway, suggesting a potential therapeutic target.
Purpose of the Study:
- To investigate the protective effects of a SOCS1 peptidomimetic against MsPGN.
- To determine if SOCS1 peptidomimetic treatment can modulate the JAK2/STAT1 pathway and macrophage activity in MsPGN.
Main Methods:
- An MsPGN rat model was established to study kidney injury and JAK2/STAT1 pathway activation.
- Rats were treated with a SOCS1 peptidomimetic.
- In vitro and in vivo experiments assessed macrophage infiltration, polarization, and JAK2/STAT1 pathway phosphorylation.
Main Results:
- SOCS1 peptidomimetic treatment reduced pathological glomerular changes and macrophage recruitment in MsPGN rats.
- In vivo, JAK2/STAT1 pathway phosphorylation was downregulated in glomerular macrophages.
- In vitro, the peptidomimetic inhibited M1 macrophage polarization by suppressing JAK2/STAT1 activation.
Conclusions:
- The SOCS1 peptidomimetic demonstrates a protective role in MsPGN by reducing macrophage infiltration and M1 polarization.
- This therapeutic approach offers a potential strategy for alleviating renal inflammation in MsPGN.
More Related Videos
10:35Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
Published on: December 26, 2017
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024